Clinical Trial Details
Trial ID: | L0451 |
Source ID: | NCT01857024 |
Associated Drug: | Sevelamer Carbonate (Renvela®) |
Title: | Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia |
Acronym: | |
Status: | COMPLETED |
Study Results: | NO |
Results: | |
Conditions: | Hyperphosphataemia|Chronic Kidney Disease |
Interventions: | DRUG: sevelamer carbonate (Renvela®) |
Outcome Measures: | Primary: Frequency of non-serious and Serious Adverse Drug Reaction (ADRs), Assess safety profile of Renvela tablets and powder, 12 Months | |
Sponsor/Collaborators: | Sponsor: Genzyme, a Sanofi Company |
Gender: | ALL |
Age: | ADULT, OLDER_ADULT |
Phases: | |
Enrollment: | 210 |
Study Type: | OBSERVATIONAL |
Study Designs: | Observational Model: |Time Perspective: p |
Start Date: | 2010-09 |
Completion Date: | 2012-10 |
Results First Posted: | |
Last Update Posted: | 2015-03-23 |
Locations: | Graz, Austria|Linz, Austria|Aalborg, Denmark|Cabestany, France|Dijon, France|Lille, France|St. Laurent du Var, France|Toulouse, France|Berlin, Germany|Dortmund, Germany|Hannover, Germany|Mettman, Germany|Wiesbaden, Germany|Acireale, Italy|Milano, Italy|Naples, Italy|Palermo, Italy|Pavia, Italy|Pesaro, Italy|Rome, Italy|Amsterdam, Netherlands|Breda, Netherlands|Dordrecht, Netherlands|Leiden, Netherlands|Madrid, Spain|Valencia, Spain |
URL: | https://clinicaltrials.gov/show/NCT01857024 |

Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
---|